Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

TORNTPHARM NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
1.9L Cr
Volatility
Moderate
P/E Ratio
75.87
EBITDA
₹4,465 Cr
Return on Equity
12.16%
Debt to Equity
1.79
Book Value
₹221.09
EPS
₹49.44
52W High
₹5,250
52W Low
₹3,480.6

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Torrent Pharmaceuticals Ltd insights

50 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • Company has been maintaining a healthy dividend payout of 57.8%

Weaknesses

4
  • Stock is trading at 19.5 times its book value
  • Promoter holding has decreased over last quarter: -7.53%
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
20.34% ↗
Net Income Growth
11.87% ↘
Cash Flow Change
16.93% ↗
ROE
-51.71% ↘
ROCE
-68.19% ↘
EBITDA Margin (Avg.)
-0.92% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Torrent Pharmaceuticals trades at a market cap of ₹1,84,612 Cr with a PE of 86.3x and PB of 22.1x, reflecting premium valuations. The company delivers strong ROE of 27% (last year) with TTM sales growth accelerating to 33%, though historical 5-year sales CAGR remains modest at 12%.

Bull Case 7
  • TTM sales growth has accelerated sharply to 33%, significantly above the 5-year CAGR of 12%, indicating a potential inflection in revenue trajectory
  • Consistently high ROE at 27% last year, with 3-year average of 26% and 5-year average of 24%, demonstrating efficient capital allocation
  • Compounded profit growth of 22% over 3 years outpaces the 10-year profit CAGR of 2%, showing meaningful margin expansion in recent years
  • Healthy dividend payout ratio of 57.8% signals management confidence in cash flow sustainability and shareholder-friendly capital return policy
  • Stock CAGR of 35% over both 1-year and 3-year periods reflects sustained investor confidence and consistent re-rating
  • 10-year stock CAGR of 21% demonstrates long-term compounding ability through multiple market cycles
  • Company is expected to deliver a good quarter, suggesting near-term operational momentum remains intact
Bear Case 8
  • PE ratio of 86.3x is extremely elevated relative to pharma sector averages of 25-40x, leaving limited margin of safety for execution misses
  • Price-to-book of 22.1x (trading at 19.7x book value) implies the stock prices in many years of future growth, creating downside risk if growth disappoints
  • Promoter holding decreased by 7.53% in the last quarter, a significant reduction that may signal insider concerns or pledging-related selling
  • Historical 5-year sales growth of only 11.8-12% is modest for a company commanding an 86x PE multiple, suggesting valuation-growth disconnect
  • 10-year compounded profit growth of just 2% highlights that sustained high profitability growth is historically not the norm for this company
  • Dividend yield of only 0.78% provides minimal income cushion against potential capital depreciation at current elevated valuations
  • Potential capitalization of interest costs may be flattering reported profitability, making true earnings quality harder to assess
  • TTM profit growth of 10% lags significantly behind TTM sales growth of 33%, suggesting possible margin pressure or one-time revenue items not flowing to the bottom line

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Positives 3
  • Q1FY27 revenue surges 55% Jul 30

    Consolidated revenue of ₹4,921 crore and net profit of ₹566 crore for Q1FY27, driven by JB Pharma amalgamation and strong India business growth.

  • JB Chemicals amalgamation shares listed Jul 27

    4.19 crore equity shares issued under the JB Chemicals amalgamation scheme received final listing approval, with trading commencing on NSE and BSE on July 28, 2026.

  • ESG score of 70 assigned Aug 11

    Torrent Pharma received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited, a SEBI-registered provider.

Neutral 6
  • Institutional block trades on NSE Aug 5

    Two block trades recorded on Aug 4-5 totalling ~₹83 crore — 1,07,153 shares at ₹5,015 (Aug 4) and 59,070 shares at ₹4,961.50 (Aug 5), indicating institutional activity.

  • Senior management restructuring Jul 30

    Three senior management personnel (Hasmukh Patel, Sushil Jaiswal, Sunil Nadkarni) ceased roles effective July 30 due to reporting structure changes.

  • Shanti Ekambaram appointed director Jul 29

    Shanti Ekambaram appointed as Additional Independent Director for three years effective July 30, 2026, subject to shareholder approval via postal ballot (e-voting from Aug 8).

  • Ameera Shah completes director term Aug 1

    Ameera Shah ceased to be Independent Director on August 1, 2026, upon completion of her term.

  • Philippines subsidiary dissolved Jul 17

    Wholly owned subsidiary Curatio Inc. in the Philippines dissolved on July 10, 2026. The unit had nil turnover and net worth of ₹1.3 crore.

  • Investor meet on Aug 14 Aug 11

    Torrent Pharma to participate in Emkay Confluence 2026 investor meet in Mumbai on August 14 with group and one-on-one discussions.

TL;DR: Torrent Pharma is executing well with a 55% revenue surge in Q1FY27 driven by the successful JB Chemicals amalgamation and domestic growth. No material headwinds are visible in recent news flow. Board reconstitution and management restructuring appear routine rather than concerning. The trend is positive with the integrated entity now fully listed and operational, and investor engagement continuing.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
2,591
2,660
2,732
2,745
2,859
2,889
2,809
2,959
3,178
3,302
3,303
4,197
4,921
Expenses
1,800
1,835
1,863
1,862
1,955
1,950
1,895
1,995
2,146
2,219
2,215
2,841
3,257
Operating Profit
791
825
869
883
904
939
914
964
1,032
1,083
1,088
1,356
1,664
OPM %
31%
31%
32%
32%
32%
32%
33%
33%
32%
33%
33%
32%
34%
Other Income
34
26
55
31
24
-16
33
-42
-37
-40
-23
-83
-33
Interest
103
91
80
80
75
64
57
56
56
48
45
236
305
Depreciation
191
201
213
203
197
198
199
201
201
204
206
508
593
PBT
531
559
631
631
656
661
691
665
738
791
814
529
733
Tax %
29%
31%
30%
29%
30%
31%
27%
25%
26%
25%
22%
31%
23%
Net Profit
378
386
443
449
457
453
503
498
548
591
635
364
566
EPS in Rs
11.17
11.41
13.09
13.27
13.5
13.38
14.86
14.71
16.19
17.46
18.76
10.76
16.72
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
4,636
6,687
5,816
5,950
7,673
7,939
8,005
8,508
9,620
10,728
11,516
13,980
15,723
Expenses
3,616
3,954
4,438
4,601
5,690
5,769
5,524
6,077
6,778
7,360
7,795
9,421
10,532
Operating Profit
1,020
2,733
1,377
1,349
1,983
2,170
2,480
2,431
2,842
3,368
3,721
4,558
5,191
OPM %
22%
41%
24%
23%
26%
27%
31%
29%
30%
31%
32%
33%
33%
Other Income
286
32
223
299
-300
121
57
-288
45
146
-1
-182
-179
Interest
175
184
206
308
504
451
353
255
333
354
252
385
634
Depreciation
191
238
307
409
618
654
658
662
707
808
795
1,119
1,511
PBT
940
2,343
1,088
931
562
1,187
1,526
1,226
1,847
2,352
2,673
2,872
2,867
Tax %
20%
26%
14%
27%
22%
14%
18%
37%
33%
30%
28%
26%
—
Net Profit
751
1,733
934
678
436
1,025
1,252
777
1,245
1,656
1,911
2,138
2,156
EPS in Rs
22.19
51.22
27.59
20.04
12.89
30.28
36.99
22.97
36.79
48.94
56.47
63.92
63.7
Div. Payout %
25%
34%
25%
35%
66%
53%
47%
105%
60%
57%
57%
59%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
85
85
85
85
85
85
85
169
169
169
169
Reserves
2,406
3,409
4,266
4,538
4,640
4,739
5,753
5,868
6,029
6,687
7,421
8,219
Borrowings
2,740
2,352
2,510
6,462
6,038
5,784
4,874
4,070
5,369
4,022
3,202
15,026
Other Liabilities
2,589
3,040
2,740
3,159
3,351
3,402
3,363
2,884
3,043
3,627
3,603
20,200
Total Liabilities
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
Fixed Assets
2,833
2,859
3,688
7,855
7,748
7,533
7,065
6,423
8,121
8,138
7,947
33,191
CWIP
678
1,042
519
647
617
712
889
630
765
361
478
641
Investments
298
780
804
492
353
2
181
226
199
173
156
948
Other Assets
4,011
4,206
4,589
5,249
5,395
5,763
5,940
5,628
5,524
5,834
5,815
8,833
Total Assets
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
810
2,742
1,009
894
1,798
1,393
2,005
1,803
2,368
3,266
2,585
3,023
Investing
-2,113
-869
-798
-4,677
-246
229
-444
-196
-2,335
-160
-549
-12,630
Financing
1,212
-1,435
-193
3,417
-1,314
-1,549
-1,651
-1,781
77
-2,780
-2,298
10,151
Net Cash Flow
-90
437
18
-366
238
73
-89
-174
110
327
-262
544
Free Cash Flow
574
2,150
523
105
1,138
990
1,671
1,607
1,953
2,967
1,991
2,386
CFO/OP
85
121
101
87
105
77
88
91
97
112
86
84
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
125
79
60
77
68
76
69
70
74
63
59
79
Inventory Days
275
314
318
429
318
362
456
368
298
310
334
338
Days Payable
472
523
356
447
345
345
351
250
224
284
239
254
Cash Conversion Cycle
-71
-130
21
59
42
93
174
188
147
89
154
163
Working Capital Days
29
-1
28
-80
-62
-52
-5
7
-33
-27
7
-26
ROCE %
27%
48%
19%
13%
13%
15%
17%
19%
20%
23%
27%
15%

Shareholding Pattern

As of Jul 2026
Promoters 60.78%
FIIs 17.97%
DIIs 12.87%
Public 6.82%
Others 1.56%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Jul 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
Promoters
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
71.25%
68.31%
68.31%
68.31%
68.31%
68.31%
68.31%
68.31%
60.78%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
14.14%
14.22%
14.46%
16.17%
16.31%
16.09%
15.92%
16.13%
16.18%
15.44%
17.97%
DIIs
6.53%
6.71%
6.76%
6.78%
7.52%
7.82%
7.76%
8.89%
8.87%
9.00%
8.31%
7.16%
6.44%
7.26%
7.27%
7.08%
8.35%
8.35%
8.65%
9.28%
9.14%
9.06%
9.83%
12.87%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
7.89%
7.72%
7.58%
7.29%
7.25%
7.10%
7.13%
4.59%
4.73%
4.47%
4.38%
4.25%
4.15%
4.09%
3.98%
4.34%
4.61%
4.51%
4.44%
4.08%
4.03%
4.12%
5.04%
6.82%
Others
14.33%
14.33%
14.42%
14.68%
13.98%
13.83%
13.86%
15.27%
15.16%
15.28%
16.07%
17.34%
18.16%
3.27%
3.28%
2.87%
2.56%
2.52%
2.50%
2.41%
2.38%
2.33%
1.38%
1.56%
No. of Shareholders
0
72,616
64,525
64,309
67,205
63,229
62,933
64,557
67,866
63,831
61,572
69,612
69,117
71,154
74,765
79,848
85,035
86,005
81,856
78,226
76,214
83,811
85,776
1,40,599

Documents

Frequently Asked Questions about Torrent Pharmaceuticals Ltd

What does Torrent Pharmaceuticals Ltd do?
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesse...
Where is Torrent Pharmaceuticals Ltd (TORNTPHARM) listed?
Torrent Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: TORNTPHARM and BSE: 500420. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Torrent Pharmaceuticals Ltd belong to?
Torrent Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a market capitalisation of approximately ₹185657.55 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Torrent Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 75.87. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹3,480.6 and a high of ₹5,250. This range helps investors understand the stock's price volatility and recent trading levels.
Does Torrent Pharmaceuticals Ltd pay dividends?
Yes, Torrent Pharmaceuticals Ltd has a dividend yield of 0.77%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a Return on Equity (ROE) of 12.16%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Torrent Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Torrent Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]

Website torrentpharma.com
CEO Mr. Aman Mehta
Employees 17,059
Listed 2002-11-25
Face Value ₹ 5
Issued Size 33,84,45,440

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List